Life sciences · Journal article

Mucus-penetrating nanocarriers for the enhanced oral delivery of antibody drugs

Nanomedicine · September 9, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative review of mucus-penetrating nanocarrier technologies for oral antibody delivery, examining preclinical design principles and structural barriers in the gastrointestinal mucus layer. The article identifies technological strategies (PEGylation, zwitterionic, biomimetic, charge-switching, lipid- and polymer-based systems) and articulates biological and translational challenges, but reports no original experimental results or clinical evidence supporting efficacy or safety.

What was studied

Journal article. Conceptual: therapeutic monoclonal antibodies for cancer, autoimmune, inflammatory, and chronic diseases; no clinical population studied.

Key findings

Gastrointestinal mucus layer is identified as an often-overlooked determinant of oral bioavailability for antibody therapeutics Multiple nanocarrier design approaches are reviewed: PEGylated, zwitterionic, biomimetic, charge-switching, lipid- and polymer-based nanocarriers, and multifunctional platforms Text notes that nearly all approved antibody therapies require parenteral administration due to gastrointestinal barriers

Safety

No safety, bioavailability, or immunogenicity data presented for any formulation

Who this may help

This review contextualizes the scientific rationale for oral antibody delivery systems but provides no clinical evidence to guide practice. Clinicians should recognize this as an overview of emerging technology rather than validated clinical guidance.

Plain-language summary

This is a narrative review article examining design principles for mucus-penetrating nanocarriers to enhance oral antibody delivery, raising questions about preclinical advances rather than reporting primary experimental results or clinical evidence.

Clinical bottom line

Caveats

No primary experimental data, efficacy measures, or clinical outcomes reported
Preclinical advances discussed but no quantitative comparisons between nanocarrier platforms provided
Article does not report whether any mucus-penetrating systems have achieved clinical translation or regulatory approval
No safety, bioavailability, or immunogenicity data presented for any formulation

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Narrative review; no primary experimental design or clinical trial reported.

Directness

limited

Review of preclinical advances; no direct clinical outcome data presented.

Consistency

insufficient

Text does not compare or reconcile conflicting findings across studies.

Risk of bias

insufficient

Narrative review format; no systematic methodology or bias assessment reported.

Sample adequacy

insufficient

Review article with no quantitative data from a defined population.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Monoclonal antibodies have transformed the treatment of cancer, autoimmune and inflammatory diseases, and other chronic conditions due to their high target specificity and favorable therapeutic profiles. However, nearly all approved antibody therapies require parenteral administration because the gastrointestinal tract presents formidable barriers to oral delivery. Although considerable research has focused on protecting antibodies from degradation and enhancing epithelial transport, the gastrointestinal mucus layer is an often-overlooked determinant of oral bioavailability. As the first extracellular barrier encountered by orally administered formulations, mucus regulates particle diffusion, retention, and clearance, potentially preventing therapeutic antibodies from reaching the epithelial surface. Recent advances in nanotechnology have enabled mucus-permeating delivery systems that minimize interactions with mucins while preserving antibody stability and facilitating epithelial transport. These include PEGylated, zwitterionic, biomimetic, charge-switching, lipid- and polymer-based nanocarriers, as well as multifunctional platforms integrating mucus penetration with controlled release and targeted cellular uptake.This review provides a comprehensive overview of the structural and physiological characteristics of the gastrointestinal mucus barrier and examines how its complex architecture influences the transport of antibody-loaded nanocarriers. Current design principles for mucus-permeating oral delivery systems are discussed, highlighting recent preclinical advances and the key biological and technological challenges limiting clinical translation.[PubMed, Scopus, Google Scholar, ClinicalTrials.gov, and WHO International Clinical Trials Registry Platform (ICTRP); January 2001-December 2026].

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

M ValleCristina PanguaMiriam ArellanoJuan M. IracheAinhoa Huidobro